Both Chloroquine and Lopinavir/Ritonavir Are Ineffective for COVID-19 Treatment and Combined Worsen the Pathology: A Single-Center Experience with Severely Ill Patients

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

(2020) Manli Wang et al.   CELL RESEARCH

Efficacy, safety and cost‐effectiveness of hydroxychloroquine in children with COVID‐19: a call for evidence

(2020) Carlos E. Rodríguez‐Martínez et al.   ACTA PAEDIATRICA

Anti COVID-19 Drugs: Need for More Clinical Evidence and Global Action

(2020) Zakir Khan et al.   ADVANCES IN THERAPY

Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis

(2020) Bolin Wang et al.   Aging-US

Why Are Lopinavir and Ritonavir Effective against the Newly Emerged Coronavirus 2019? Atomistic Insights into the Inhibitory Mechanisms

(2020) Bodee Nutho et al.   BIOCHEMISTRY

Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis

(2020) Brandon Michael Henry et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Does lopinavir measure up in the treatment of Covid-19?

(2020) Sheila A Doggrell   EXPERT OPINION ON INVESTIGATIONAL DRUGS

New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?

(2020) Christian A. Devaux et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

(2020) Philippe Gautret et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis

(2020) Jing Yang et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)

(2020) James M. Sanders et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19

(2020) Zhen Zhu et al.   JOURNAL OF INFECTION

Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

(2020) Ivan Fan-Ngai Hung et al.   LANCET

Chloroquine paradox may cause more damage than help fight COVID-19

(2020) Anuj Sharma   MICROBES AND INFECTION

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19

(2020) Bin Cao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19

(2020) Joshua Geleris et al.   NEW ENGLAND JOURNAL OF MEDICINE

“Off-label” use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers

(2020) Alexandre Gérard et al.   THERAPIE

The COVIRL-001 Trial: A multicentre, prospective, randomised trial comparing standard of care (SOC) alone, SOC plus hydroxychloroquine monotherapy or SOC plus a combination of hydroxychloroquine and azithromycin in the treatment of non- critical, SARS-CoV-2 PCR-positive population not requiring immediate resuscitation or ventilation but who have evidence of clinical decline: A structured summary of a study protocol for a randomised controlled trial

(2020) Eoin Feeney et al.   Trials

Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France

(2020) Matthieu Million et al.   Travel Medicine and Infectious Disease

Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study

(2020) Philippe Gautret et al.   Travel Medicine and Infectious Disease

Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data

(2020) Matthieu Mahévas et al.   BMJ-British Medical Journal

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

(2020) Jia Liu et al.   Cell Discovery

Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants

(2020) Muhammad Tahir ul Qamar et al.   Journal of Pharmaceutical Analysis

Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol

(2020) Niyada Naksuk et al.   European Heart Journal-Acute Cardiovascular Care

Emerging pharmacotherapies for COVID-19

(2020) Rachana Salvi et al.   BIOMEDICINE & PHARMACOTHERAPY

Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression

(2020) Fang Liu et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

A retrospective evaluation on the efficacy of Lopinavir/ritonavir and chloroquine to treat non-severe COVID-19 patients

(2020) Guiju Gao et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study

(2020) Xi Liu et al.   Trials

No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study

(2020) Yin-Qiu Huang et al.   Frontiers in Pharmacology

Obesity in Mexico: prevalence, comorbidities, associations with patient outcomes, and treatment experiences

(2017) Marco D DiBonaventura et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

Combination therapy with lopinavir/ritonavir, ribavirin and interferon-alpha for Middle East respiratory syndrome: a case report

(2015) Uh Jin Kim et al.   ANTIVIRAL THERAPY

Burden of type 2 diabetes in Mexico: past, current and future prevalence and incidence rates

(2015) Rafael Meza et al.   PREVENTIVE MEDICINE

Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients

(2013) JC Silva et al.   Clinics

Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial

(2011) Nicholas I Paton et al.   LANCET INFECTIOUS DISEASES

On Chikungunya Acute Infection and Chloroquine Treatment

(2008) Xavier De Lamballerie et al.   VECTOR-BORNE AND ZOONOTIC DISEASES